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OBJECTIVE—Dipeptidylpeptidase-4(DPP-4)inhibitorsareanewclassofantidiabeticdrugs.
Theyinactivate incretinhormonesbut alsohave manyother effectsthroughoutthebody,among
which are effects on the immune system. This might result in an increased infection risk. This
study assessed the association between use of DPP-4 inhibitors and the reporting of infections.
RESEARCH DESIGN AND METHODS—A nested case-control was conducted using
VigiBase, the World Health Organization-Adverse Drug Reactions (WHO-ADR) database. The
base cohort consisted of ADRs for antidiabetic drugs (Anatomical Therapeutic Chemical code
A10).CasesweredeﬁnedasADRsofinfectionaccordingtotheMedicalDictionaryforRegulatory
Activities (MedDRA) classiﬁcation system. All other ADRs were considered controls. Reporting
odds ratios (RORs) were calculated to estimate the strength of the association between different
classes of antidiabetic drugs and the reporting of infections.
RESULTS—We identiﬁed 305,415 suspected ADRs involving antidiabetic drugs in 106,469
case reports, of which 8,083 involved DPP-4 inhibitors monotherapy. Overall, the reporting of
infections was higher for patients using DPP-4 inhibitors compared with users of biguanides
(ROR 2.3 [95% CI 1.9–2.7]). Reporting of upper respiratory tract infections (ROR 12.3 [95% CI
8.6–17.5]) was signiﬁcantly associated with use of DPP-4 inhibitors.
CONCLUSIONS—This study indicates an increased reporting of infections, in particular
upper respiratory tract infections, for users of DPP-4 inhibitors compared with users of other
antidiabetic drugs. However, the limitations of spontaneous reporting systems (e.g., underre-
porting, the Weber-effect, reporting bias) should be taken into account. Therefore, further re-
search is needed to evaluate this suspicion and the underlying mechanism.
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D
ipeptidylpeptidase-4(DPP-4)inhib-
itors are a new class of antidiabetic
drugs, with three products currently
available on the market: sitagliptin, vilda-
gliptin, and saxagliptin (1–3). The inacti-
vation ofincretin hormones (glucagon-like
peptide-1 and glucose-dependent insuli-
notropic polypeptide) by DPP-4 inhibitors
results in a rise in insulin from pancreatic
b-cells and a decrease in glucagon from
pancreatic a-cells. As a consequence,
DPP-4inhibitorsimproveglycemiccontrol
by reducing fasting and postprandial glu-
cose concentrations in patients with type 2
diabetes (1).
DPP-4isassumedto havemany other
functions in the human physiology due
to its presence on the surface of many
different cell types, but these effects are
still largely unknown. The role of DPP-4
in immune regulation is better deﬁned
and includes induction of transforming
growth factor-b1 in activated T cells and
suppression of production of inﬂamma-
torycytokinesbyTcells(4),effectsoncell
growth, differentiation, and apoptosis
(5,6). The immunomodulating effect has
givenrisetoconcernsregardingapossible
increase in the occurrence of infections
(1–3).
Nasopharyngitis, upper respiratory
tract (URTI), and related infections (acute
bronchitis, pharyngitis, sinusitis, and rhi-
nitis) were the most commonly reported
infections for the active substances com-
pared with the reference intervention in
clinical trial programs (1–3). However,
pooled analyses for vildagliptin and
saxagliptin did not indicate an increased
risk of infections compared with the ref-
erence group (7,8). In the three European
Union (EU) Risk Management Plans (a
mandatory partof marketing applications
since November 2005 [9]) for the ap-
proved DPP-4 inhibitors, “infections”
were deﬁned as important identiﬁed risks
that require further evaluation. Postau-
thorizationsafetystudiesspeciﬁcallyeval-
uating the risk of hospitalization due to
infections are currently being conducted
for vildagliptin and saxagliptin (2,3). For
sitagliptin, the risk for infections will be
further evaluated through an in-depth
analysis of the safety results of the ongo-
ing and planned clinical trials (1).
Data on a possible direct relation
between diabetes mellitus and infections
are inconclusive. Several studies investi-
gated a possible association between di-
abetes mellitus and alterations of the
immune system (10,11). Some epidemi-
ologic studies showed that these patients
are at an increased risk for common
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ORIGINAL ARTICLEinfections (12–15), but evidence from
clinical trials is limited and inconsistent
(16). Disease progression may have an ef-
fect on the occurrence of infections; thus,
more severely ill patients might be at an
increased risk of infections (17). To our
knowledge, no studies have speciﬁcally
investigated the relation between the use
of DPP-4 inhibitors and infections as ad-
verse drug reactions (ADRs). Therefore,
the aim of the current study was to assess
the relation between different classes of
antidiabetic drugs and the reporting of
infections.
RESEARCH DESIGN AND
METHODS
Setting and study design
DatawereobtainedfromtheInternational
Drug Monitoring Program of the World
Health Organization (WHO). The WHO
globalindividualcasesafetyreport(ICSR)
database, VigiBase, is maintained by the
Uppsala Monitoring Centre and contains
summariesofsuspectedspontaneouscase
reports originally summated by health
careprofessionalsandpatientstonational
pharmacovigilance centers in 98 coun-
tries worldwide. As of May 2010, this
database contained .5 million case re-
ports of suspected ADRs regarding spe-
ciﬁc, but anonymous, patients. The
reports contain administrative data, pa-
tient data, ADR data, medication data,
and additional information. The informa-
tioninthesereportsisnothomogenous,at
least with regard to origin, completeness
of documentation, or the likelihood that
the suspected drug caused the adverse
events (18). ADRs are coded according
to the Adverse Reaction Terminology
(WHO-ART) and Medical Dictionary for
Regulatory Activities (MedDRA; www.
who-umc.org).
This study was designed as a nested
case-control study. The base cohort con-
sisted of all ADRs associated with the use
of any antidiabetic drug (Anatomical
Therapeutic Chemical [ATC] code A10),
including oral antidiabetic drugs and in-
sulins, in the period 1999 through 2009.
Deﬁnition of cases and controls
Cases were deﬁned as ADRs classiﬁed as
an infection. Infections were deﬁned by
means of MedDRA adverse reaction
terms, including all relevant high-level
group terms and lower-level terms. All
infections from the System Organ Class
(SOC) “Infectionsand Infestations” and in-
fections reported in other SOCs identiﬁed
through a manual search were deﬁned as
cases. All reports containing other ADRs
were considered as controls. We grouped
the infections on the ﬁrst sublevel (high-
level group terms) of MedDRA and looked
at URTI (e.g., sinusitis and nasopharyngi-
tis), lower respiratory tract infections
(LRTI, e.g., bronchitis and pneumonia),
andurinarytractinfections(UTI;e.g.,cys-
titis and pyelonephritis). Because of low
numbers, all other infections were com-
bined.
Exposure deﬁnition
Exposure to antidiabetic drugs was the
determinant that was investigated. Anti-
diabetic drugs were subclassiﬁed based
on the Anatomical Therapeutic Chemical
(ATC) classiﬁcation system of the WHO
(www.whocc.no): biguanides (ATC code
A10BA), sulfonylurea derivatives (A10BB),
thiazolidinediones (A10BG), DPP-4 in-
hibitors (A10BH), insulins, and analogs
(A10A).Whenmultipleantidiabeticdrugs
were reported for a certain ADR, this was
classiﬁed as combination therapy, irrespec-
tive of whether a drug reported was classi-
ﬁed as “suspected” or as a comedication.
Potential confounding factors
Potential confounding factors retrieved
from the case reports included age and
gender of the patient, reporting year,
reportingregion(Europe,NorthAmerica,
rest of the world), and reporter type,
includingphysician,pharmacist,othercare-
giver, pharmaceutical company (indirectly
obtained from a health care professional),
and patient/consumer. Concomitant use
of medication affecting the immune sys-
tem,deﬁnedasreportingoneofthesedrugs
as a concomitant drug for an ADR, was
taken into account when recorded, in-
cluding antibiotics (ATC code J01), corti-
costeroids for systemic use (H02), and
immunosuppressants (L04).
Data analysis
Descriptive statistics were used to sum-
marize the baseline characteristics of the
case reports. Unconditional logistic re-
gression analysis was used to estimate the
strength of the association between use of
antidiabetic drugs and reporting of infec-
tions and expressed as reporting odds
ratios (RORs) with corresponding 95%
CIs. Biguanides were the reference group.
Owing to low numbers, combination
therapy was analyzed on an aggregated
level, not on an individual drug-drug
combination level. We focused on infec-
tions in general and more speciﬁcally on
thehigh-levelgrouptermsURTI,LRTI,and
UTI. Adjusted analyses were conducted
with all potential confounders included in
the model.
More ADRs were usually reported for
o n ec a s er e p o r t ,a n dt h e r e f o r ei tw a s
possible that one case report contained
more than one ADR of an infection. To
test the effect of multiple ADRs reported
in one case report, we analyzed the data
on the level of case reports (one case
report generally represented one patient).
In the U.S., DPP-4 inhibitors are in-
dicated for monotherapy for the treat-
ment of diabetes mellitus, whereas in the
EU,thesemedicinesareonlyindicatedfor
combination therapies.Tocheck whether
this affected the results of this study, we
performed a sensitivity analysis by ana-
lyzing the data for the U.S. and the rest of
theworldseparately.Inaddition,tostudy
the effect of the type of reporter (health
care professional or consumer) on the
outcome,weperformedasensitivityanal-
ysis in which the reports were assessed
according to the type of reporter. Statisti-
cal analysis was done using SPSS 16.0
statisticalsoftware(SPSSInc.,Chicago,IL).
RESULTS—From the WHO VigiBase
we identiﬁed 305,415 suspected ADRs
related to the use of antidiabetic drugs in
106,469 case reports in the study period
1999through2009.Patientswereamean
age of 59.7 years (SD, 14.3) and 59.6%
were women. A total of 288,434 reports
(94.4%)reportsinvolvedoneantidiabetic
drug, 14,057 (4.6%) reported a combi-
nation of two antidiabetic drugs, and
2,924 (1.0%) reported three or more
antidiabetic drugs (Table 1). Overall, the
most commonly reported infections on
the level of MedDRA lower-level terms
were pneumonia (11.8%), nasopharyngi-
tis (10.1%), UTIs (6.2%), infection not
otherwise speciﬁed (5.5%), sinusitis
(5.1%), and bronchitis (4.8%). All other
types of infection were reported in
,4.5% of the reports related to infections.
A total of 242 infections were reported
as a MedDRA term in 212 case reports
for DPP-4 inhibitors, of which 188
(88.7%) reported one infection. Of the
24 case reports (11.3%) with multiple
infections, 12 (50%) reported a nonspe-
ciﬁc infection term, such as “infection” or
“URTI,” combined with a more speciﬁc
infection term, such as “nasopharyngi-
tis” or “cystitis” (see the Supplementary
Data for a summary of the infections ac-
cording to the MedDRA lower-level
term).
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DPP-4 inhibitors and reporting of infectionsTable2reportstheRORsofinfections
(overall) per antidiabetic drug compared
with biguanides. The use of DPP-4 inhib-
itors as monotherapy (ROR 2.3 [95% CI
1.9–2.7]), insulins as monotherapy (ROR
1.6 [95% CI 1.4–1.8]), and the combina-
tion of any oral antidiabetic drug and in-
sulintherapy(ROR1.8[95%CI1.3–2.4])
were all statistically signiﬁcant associated
with ADR reports of infections compared
with biguanides. A slightly increased re-
porting of infections for patients using
thiazolidinediones was found (ROR 1.2
[95% CI 1.1–1.4]), but no increased re-
porting of infections was found for sulfo-
nylurea derivatives (ROR 1.2 [95% CI
1.0–1.4]), combination therapy of two
oral antidiabetic drugs (ROR 1.0 [95%
CI 0.8–1.2]), or for concomitant use of
three or more antidiabetic drugs (ROR
1.0 [95% CI 0.7–1.4]). Adjustment for
the potential confounding factors did
not affect the results.
Assessment of different types of in-
fections (Table 3) showed an increased
reporting of URTI (ROR 12.3 [95% CI
8.6–17.5]) for the DPP-4 inhibitors,
whereas the reporting for LRTI, UTI,
and other infections was not increased.
In addition, an increased reporting of
URTI was found for users of thiazolidine-
diones (ROR 2.3 [95% CI 1.7–3.3]), and
for concomitant use of three or more an-
tidiabetic drugs (ROR 2.5 [95% CI 1.3–
4.7]).SlightlyincreasedRORswerefound
for the use of insulin monotherapy and
the reporting of URTI (ROR 1.5 [95%
CI 1.1–2.2]) and UTI (ROR 1.7 [95% CI
1.1–2.5]). The reporting of LRTI (ROR
1.8 [95% CI 1.4–2.3]) and other infec-
tions (ROR 1.7 [95% CI 1.4–2.0]) was
also increased for insulin monotherapy.
For the combination of an oral antidia-
betic drug and insulin, increased report-
ing of UTI (ROR 3.5 [95% CI 1.7–7.2])
and other infections (ROR 1.7 [95% CI
1.1–2.6]) was noted. The other associa-
tions between antidiabetic drugs and in-
fections were nonsigniﬁcant (Table 3).
The crude ROR was lower for DPP-4
inhibitors but was still signiﬁcantly in-
creased (ROR 1.6 [95% CI 1.3–1.9]) in
the analysis of the data on the level of
case reports. The RORs for other antidia-
betic drugs did not change, except for in-
sulin. The ROR for insulin monotherapy
increased to 2.1 (95% CI 0.8–2.4). The
sensitivityanalysesshowedthatthecoun-
try from which the case reports originates
and the type of reporter did not have a
major effect on the results (data not
shown). The point estimates changed
onlyslightly,butbecauseofthedecreased
numbers the conﬁdence intervals became
wider.
CONCLUSIONS—This study showed
that infections were approximately two
times morefrequentlyreported for DPP-4
inhibitors compared with biguanides in
the WHO Vigibase. In particular, URTIs,
including nasopharyngitis and sinusitis,
were reported more frequently for DPP-4
inhibitors, although the reporting of
URTI was also increased for users of
thiazolidinediones, insulin monotherapy,
and concomitant use of three or more
antidiabetic drugs, but to a much lesser
extent than for the DPP-4 inhibitors.
A hypothesis resulting from the cur-
rent study is that the effect of DPP-4
inhibitors results in a slight imbalance of
the immune system that causes an in-
creased risk of common, less severe in-
fections such as (viral) upper respiratory
infections. This is supported by the re-
sults of the pivotal randomized clinical
trials that also reported increased num-
bers of common infections rather than
serious infections (1–3). As far as we are
aware, no studies reporting serious infec-
tions in association with the use of DPP-4
inhibitors have been reported. At this
Table 1—Baseline characteristics of all
spontaneous reports for antidiabetic drugs
in the WHO VigiBase (1999–2009)
Variable
Spontaneous
reports
(N = 305,415)
Patient age, mean (SD),
years 59.7 (14.3)
Age (missing) 63,212 (20.7)
Female sex 182,130 (59.6)
Sex (missing) 9,100 (3.0)
Reporter
Health care professional 92,896 (30.4)
Nonhealth care
professional 129,287 (42.3)
Study/literature 218 (0.1)
Unknown 45,308 (14.8)
Other 37,706 (12.3)
Reporting year
1999–2004 93,255 (30.5)
2005–2009 212,160 (69.5)
Region
Europe 19,252 (6.3)
United States 273,079 (89.4)
Other 13,084 (4.3)
Antidiabetic drugs
involved
Monotherapy 288,434 (94.4)
Biguanides 21,763 (7.1)
Sulfonylurea derivative 16,675 (5.5)
Thiazolidinediones 57,814 (18.9)
Dipeptidyl peptidase-4
inhibitors 8,083 (2.6)
Insulin 80,347 (26.3)
Dual therapy 14,057 (4.6)
2 oral antidiabetics 11,991 (3.9)
Biguanide,
sulfonylurea derivative 2,413 (0.8)
Biguanide,
thiazolidinediones 1,087 (0.4)
Sulfonylurea derivatives,
thiazolidinediones 866 (0.3)
Oral antidiabetic +
insulin 2,066 (0.7)
Triple therapy 2,924 (1.0)
Concomitant medication
Antibiotics (J01) 5,072 (1.7)
Immunosuppressants
(L04) 2,013 (0.7)
Corticosteroids for
systemic use (H02) 4,527 (1.5)
Alldataexceptpatientageareshownasnumber(%).
Table 2—Crude and adjusted RORs for any infection
ROR (95% CI)
Drug Reports (N) Reports of infections (N) Crude Adjusted*
Biguanides 21,763 289 Reference Reference
SU derivatives 16,675 258 1.2 (1.0–1.4) 1.1 (0.9–1.3)
TZDs 57,814 919 1.2 (1.1–1.4) 1.3 (1.1–1.5)
DPP-4 I 8,083 242 2.3 (1.9–2.7) 2.3 (1.9–2.9)
Insulins 80,347 1,703 1.6 (1.4–1.8) 1.5 (1.3–1.7)
OAD + OAD 11,991 155 1.0 (0.8–1.2) 0.9 (0.7–1.1)
OAD + insulin 2,066 48 1.8 (1.3–2.4) 1.5 (1.1–2.2)
$3 ADs 2,924 39 1.0 (0.7–1.4) 1.1 (0.9–1.4)
ADs, antidiabetic drugs; DPP-4 I, dipeptidyl peptidase inhibitors; OAD, oral antidiabetic drug; SU, sulfo-
nylurea; TZD, thiazolidinediones. *Adjusted forage, sex, reporting year, reporting region, reporter type, and
comedication affecting the immune system: antibiotics (J01), corticosteroids for systemic use (H02), and
immunosuppressants (L04).
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Willemen and Associatestime, the magnitude of the effects of DPP-
4 inhibitors on the immune system may
not be compared with the magnitude of
the effects as seen, for example, with bio-
logic agents, resulting in rather serious
infectionssuchastuberculosisorhistoplas-
mosis due to tumor necrosis factor-a an-
tagonists (19,20). With the current data,
however, it was not possible to further dif-
ferentiate between infections of different
natureandviral,bacterial,orfungalcauses.
The strength of this study is that the
WHO VigiBase allows studying the asso-
ciation between use of antidiabetic drugs
andinfectionsoutsidethehighlycontrolled
environment of clinical trials. Neverthe-
less, some limitations of this study need
to be addressed:
First, besides the known issue of
underreporting in spontaneous reporting
systems (21), the reporting pattern of
A D R sm a yd i f f e rb e t w e e nn e wa n do l d
drugs,withthemostvigorousmonitoring
atthetimeofmarketingandshortlythere-
after, as described by Weber (21). The
DPP-4 inhibitors and thiazolidinediones
were introduced in the study period
(1999 through 2009), which might ex-
plain the relatively large number of re-
ports for those drugs. However, it is
unknown whether the type of ADRs that
are reported changes over time and how
thisaffects theresults ofthisstudy.None-
theless, adjustment for year of reporting
did not affect the results.
Second, the results of this study may
be subject to reporting bias, because
infections are listed in both the EU and
U.S. Summaries of Product Character-
istics for all three DPP-4 inhibitors. This
may have led to differential monitoring
and reporting of infections for the DPP-4
inhibitors compared with other antidia-
betic drugs. Increased reporting (physi-
cians report ADRsthat arelikely to occur)
or decreased reporting (physicians do not
report ADRs that are already mentioned
in Summaries of Product Characteristics)
might have occurred. In absolute terms,
the number of reported infections is low:
only 3% of the cases for DPP-4 inhibitors
reportsinvolvedaninfection(242reports
of infection of 8,083 case reports).
Furthermore, differences in classiﬁca-
tion strategies or misclassiﬁcation may
have occurred by the translation from
clinical terminology to the classiﬁcation
systems used by the WHO Vigibase
(WHO-ART or MedDRA terms). We do
not expect, however, that this misclassiﬁ-
cation is different for different antidiabetic
medicines, and the effect of this nondiffer-
ential misclassiﬁcation on the results of
this study will therefore be limited. In
several case reports, more than one in-
fection term was recorded, mainly con-
sisting of a speciﬁc infection term (e.g.,
nasopharyngitis) and an a-speciﬁc term
(e.g., URTI), which might inﬂuence the
results. However, our analysis at the case-
reportlevelshowedthattheoverall results
did not change.
Unfortunately, we were not able to
analyze the risk of infections for combi-
nation therapy on an individual drug-
drug combination level owing to the low
number of cases reporting each possible
combination therapy. This is probably
b e c a u s ec o m e d i c a t i o ni so n l yp o o r l yr e -
ported in most case reports.
Finally,wereasonedthatthedifferent
indicationsfortheDPP-4inhibitorsinthe
U.S. versus the rest of the world, and a
possible effect of the type of reporter
(health care professional, consumer, or
industry) on the case reports, might have
inﬂuenced the results of this study. How-
ever, excluding reports from the U.S. and
excluding reporting from consumers and
industry did not affect the results.
Another explanation for our results
can be that diabetes itself, and its pro-
gression, are often associated with an
increased risk of infections. Although
the literature is not yet conclusive on
this, we could not exclude this possible
association; therefore, the current study
was limited to case reports of antidiabetic
medicines only, thereby eliminating the
effect of the disease itself. Some studies,
however, suggest that more severe diabe-
tesitselfisalsoassociatedwithhigherrisk
of infections (14,22), although this is not
supported by strong evidence. Because
disease severity is therefore possibly asso-
ciated with both exposure and outcome,
this can be a confounding factor.
DPP-4 inhibitors are indicated as a
second- or third-line therapy in combi-
nation with other oral antidiabetic drugs
according to treatment guidelines in dif-
ferent parts of the world (23,24). There-
fore, patients who are treated with DPP-4
inhibitors may in general be more se-
verely ill compared with patients being
treated with, for example, biguanides or
sulfonylurea derivatives. In the current
study, however, most of the case reports
indicated a DPP-4 inhibitor was the only
antidiabetic drug, which indicates mono-
therapy with DPP-4 inhibitors. A ques-
tion prompted by this study is whether
the patients treated with DPP-4 inhibitors
monotherapy were indeed the more se-
verely ill patients, because one antidia-
betic drug was sufﬁcient for these
patients. In addition, for users of a com-
bination of an oral antidiabetic and in-
sulin or combination therapy of two
antidiabetics (i.e., usually the more se-
verely ill patients), we did not found an
increased risk of infections. This is in line
with the studies that did not ﬁnd an as-
sociation between diabetes mellitus and
infection.
Table 3—Crude RORs for speciﬁc infections
URTI LRTI UTI Other infections
Drug N ROR (95% CI) N ROR (95% CI) N ROR (95% CI) N ROR (95% CI)
Biguanides 38 Reference 65 Reference 30 Reference 166 Reference
SU derivatives 35 1.2 (0.8–1.9) 58 1.2 (0.8–1.7) 35 1.5 (0.9–2.5) 141 1.1 (0.9–1.4)
TZDs 233 2.3 (1.7–3.3) 232 1.4 (1.0–1.8) 113 1.4 (1.0–2.1) 367 0.8 (0.7–1.0)
DPP-4 I 171 12.3 (8.6–17.5) 20 0.8 (0.5–1.4) 13 1.2 (0.6–2.3) 51 0.8 (0.6–1.2)
Insulins 215 1.5 (1.1–2.2) 425 1.8 (1.4–2.3) 186 1.7 (1.1–2.5) 1,015 1.7 (1.4–2.0)
OAD + OAD 33 1.6 (1.0–2.5) 33 0.9 (0.6–1.4) 29 1.7 (1.0–2.9) 65 0.7 (0.5–0.9)
OAD + insulin 4 1.1 (0.4–3.1) 8 1.3 (0.6–2.7) 10 3.5 (1.7–7.2) 27 1.7 (1.1–2.6)
$3 ADs 13 2.5 (1.3–4.7) 8 0.9 (0.4–1.9) 6 1.5 (0.6–3.6) 16 0.7 (0.4–1.2)
ADs, antidiabetic drugs; DPP-4 I, dipeptidyl peptidase inhibitors; OAD, oral antidiabetic drug; SU, sulfonylurea; TZDs, thiazolidinediones.
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DPP-4 inhibitors and reporting of infectionsBesides infections in general, the as-
sociation between diabetes and UTI has
also been described (12,14,15,22), al-
though we did not ﬁnd signiﬁcantly in-
creased reporting of ADRs for UTIs and
use of any of the antidiabetic drugs. Only
for combination therapy of an oral antidi-
abetic and insulin did we ﬁnd a slightly
increased reporting for UTI. Channeling
of this combination therapy toward the
more severely ill diabetes patients, for
which the use of insulin combined with
an oral antidiabetic drug is a marker (25),
may possibly explain this ﬁnding. This is
in line with studies suggesting that the
severity of the disease may play a role in
the occurrence of UTI (14,22). Unfortu-
nately, the subset of the VigiBase used
in this study did not contain information
on the severity of the underlying disease,
so the effect of this phenomenon in the
current study remains unclear.
Postmarketing evaluation of safety
concernsraisedduringthepreregistration
phase of medicines is import for the
assessment of the beneﬁt-risk balance of
drugs. This study adds to the knowledge
of this speciﬁc safety issue for the DPP-4
inhibitors. The results of the study, using
data reported to National Pharmacovigi-
lanceCentres,areinlinewiththeﬁndings
from the clinical trial program that
included a much more selected patient
population. However, more research is
neededtofurtherevaluatetheclinicaland
regulatory consequences of this ﬁnding,
such as severity of the infections.
As a result of the observed increased
risk in RCTs, the Risk Management Plans
for DPP-4 inhibitors also address a possi-
ble increased risk of infections. The def-
inition of the outcome (“infection”)i nt h e
postauthorization safety studies that are
being conducted as part of the Risk Man-
agement Plans is, therefore, of particular
importance.Because our studypointsout
that several types of infections (URTIs
such as sinusitis and nasopharyngitis)
are more frequently reported than others,
the outcome should not be limited to in-
fections in general but should also take
speciﬁc types of infections into account.
In addition, the nonserious infections
seem to be neglected in the postauthori-
zation safety studies because all studies
aim to investigate the risk of serious in-
fections (1–3). Although from a reg-
ulatory viewport the focus on serious
infections is understandable, the effect
of (recurrent) nonserious infections on
the quality of life can also be consider-
able.
Inconclusion,theresultsofthisstudy
show that there is an increased reporting
of infections for users of DPP-4 inhibitors
compared with users of other antidiabetic
drugs. Although the limitations of spon-
taneous reporting systems (e.g., under-
reporting, the Weber -effect, reporting
bias)shouldbetaken intoaccount,physi-
cians and patients nevertheless should
remain vigilant on the occurrence of
infections and continue to report infec-
tions as possible ADRs. Infections may be
related to diabetes, but a direct effect of
the medication on the occurrence of
infections should be considered.
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